BLOOMINGTON, Ind.--(BUSINESS WIRE)--Study investigators today reported initial data from Cook Medical’s REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company’s balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.
